4.5. Study Design 
Pain, anxiety, pain, headache pain, Cutaneous Allodynia, headache, migraine, disability
MIGRAINE
At baseline, each patient provided a diary of headache days in the previous month. All patients underwent thorough clinical data collection to identify the skin area of onset of maximum headache pain and the characteristics of headache. The 12-item Cutaneous Allodynia Symptom Checklist (ASC-12) was administered during a headache attack. Pain and disability were assessed using the Visual Analog Scale (VAS) from 0 to 10, and the MIDAS questionnaire. Mood and anxiety were assessed with the BDI-II and the HARS scores. At follow-up, each patient was evaluated every 30 days until 180 days after treatment. The patient reported headache day data for the previous month and underwent the same tests completed at baseline evaluation. All patients were allowed to use medication for the acute migraine attack and preventive therapy at the same levels as before baseline, but other methods of pain control or new preventive treatments were prohibited. The principal investigator, who was not involved in treating and assessing the outcome of patients, randomized the eligible patients into BoNT-A treatment or placebo group in a 2:1 ratio; the therapist administered the treatment in the outpatient clinic; the investigator who assessed the outcome avoided physical contact between patients during the treatment; the patients were instructed to fill in diaries recording headache occurrence before treatment and during months post-treatment. The investigator who assessed outcome, the patients, and the therapist were all blinded. The blinded investigator created the database from the headache diaries filled by the patients. Patients were randomized to BoNT-A or placebo treatment (